{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:33:59Z","timestamp":1790724839336,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K12-CA-076930"],"award-info":[{"award-number":["K12-CA-076930"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clml.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T14:14:56Z","timestamp":1708697696000},"page":"446-454.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marivel","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Missimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1976","authenticated-orcid":false,"given":"Masumi Ueda","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Salit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong T.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-8955","authenticated-orcid":false,"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Kuderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Shankaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2600-6390","authenticated-orcid":false,"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-2650","authenticated-orcid":false,"given":"Christopher T.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2024.02.013_bib0001","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1049909116646337","article-title":"Self-reported quality of life and symptom burden in ambulatory patients with multiple myeloma on disease-modifying treatment","volume":"34","author":"Kiely","year":"2017","journal-title":"Am J Hosp Palliat Care"},{"issue":"5","key":"10.1016\/j.clml.2024.02.013_bib0002","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage","volume":"121","author":"Kent","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2024.02.013_bib0003","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bmt.1704465","article-title":"Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation","volume":"33","author":"Sherman","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2024.02.013_bib0004","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.clml.2024.02.013_bib0005","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.02.013_bib0006","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/j.clml.2020.11.021","article-title":"Prevalence and survival impact of self-reported symptom and psychological distress among patients with multiple myeloma","volume":"21","author":"Richter","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2024.02.013_bib0007","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clml.2023.01.008","article-title":"The dynamics of financial toxicity in multiple myeloma","volume":"23","author":"Fiala","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2024.02.013_bib0008","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1200\/JOP.19.00328","article-title":"Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma","volume":"16","author":"Bange","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"15","key":"10.1016\/j.clml.2024.02.013_bib0009","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.02.013_bib0010","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1200\/OP.22.00737","article-title":"Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial","volume":"19","author":"Gupta","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.clml.2024.02.013_bib0011","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/OP.20.01071","article-title":"Maximizing home time for persons with cancer","volume":"17","author":"Banerjee","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.clml.2024.02.013_bib0012","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.clml.2020.09.010","article-title":"Burden of treatment among older adults with newly diagnosed multiple myeloma","volume":"21","author":"Mian","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2024.02.013_bib0013","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40264-016-0501-2","article-title":"Effectiveness of risk evaluation and mitigation strategies (REMS) for lenalidomide and thalidomide: patient comprehension and knowledge retention","volume":"40","author":"Brandenburg","year":"2017","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.clml.2024.02.013_bib0014","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1177\/1078155218815283","article-title":"A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone","volume":"25","author":"Schepers","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"10.1016\/j.clml.2024.02.013_bib0015","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","article-title":"Patient-reported factors in treatment satisfaction in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"24","author":"Chari","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.clml.2024.02.013_bib0016","first-page":"5859","article-title":"Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed\/refractory multiple myeloma","volume":"30","author":"Nathwani","year":"2022","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"12","key":"10.1016\/j.clml.2024.02.013_bib0017","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41409-023-02091-4","article-title":"Randomized phase 2 study of digital life coaching during transplantation for myeloma","volume":"58","author":"Banerjee","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2024.02.013_bib0018","doi-asserted-by":"crossref","first-page":"e33701","DOI":"10.2196\/33701","article-title":"Digital life coaching during stem cell transplantation: development and usability study","volume":"6","author":"Banerjee","year":"2022","journal-title":"JMIR Form Res"},{"key":"10.1016\/j.clml.2024.02.013_bib0019","unstructured":"Pacific Northwest Myeloma Fighters. Available at: <http:\/\/mmfighters.com>. Accessed September 26, 2023."},{"issue":"10","key":"10.1016\/j.clml.2024.02.013_bib0020","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/cncr.34134","article-title":"Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma","volume":"128","author":"O'Donnell","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2024.02.013_bib0021","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cancers14071605","article-title":"Divergent patterns in care utilization and financial distress between patients with blood cancers and solid tumors: a National Health Interview survey study, 2014-2020","volume":"14","author":"Su","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.clml.2024.02.013_bib0022","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.bbmt.2020.08.002","article-title":"Driving distance and patient-reported outcomes in hematopoietic cell transplantation survivors","volume":"26","author":"Banerjee","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2024.02.013_bib0023","first-page":"6109","article-title":"Identifying a cut-off score for the COST measure to indicate high financial toxicity and low quality of life among cancer patients","volume":"29","author":"Ng","year":"2021","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.02.013_bib0024","first-page":"349","article-title":"Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors","volume":"29","author":"Ver Hoeve","year":"2021","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"7","key":"10.1016\/j.clml.2024.02.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.23141","article-title":"Association of health insurance literacy with financial hardship in patients with cancer","volume":"5","author":"Khera","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.clml.2024.02.013_bib0026","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1200\/OP.22.00665","article-title":"Coverage and cost-of-care links: addressing financial toxicity among patients with hematologic cancer and their caregivers","volume":"19","author":"Edward","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.clml.2024.02.013_bib0027","first-page":"437","article-title":"Navigating financial toxicity in patients with cancer: a multidisciplinary management approach","volume":"72","author":"Smith","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.clml.2024.02.013_bib0028","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.6004\/jnccn.2020.7581","article-title":"A Pilot study of a comprehensive financial navigation program in patients with cancer and caregivers","volume":"18","author":"Watabayashi","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.02.013_bib0029","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood-2023-174451","article-title":"A randomized controlled trial of a financial navigation program for patients with multiple myeloma","volume":"142","author":"Djulbegovic","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.02.013_bib0030","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.02.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28452","article-title":"Accuracy of a text intervention to minimize the burden of cancer care among patients treated with immune checkpoint inhibitors","volume":"5","author":"Bange","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clml.2024.02.013_bib0032","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.02.013_bib0033","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clml.2024.02.013_bib0034","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-023-00937-0","article-title":"Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians","volume":"13","author":"Banerjee","year":"2023","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.02.013_bib0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2023-178950","article-title":"Retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma","volume":"142","author":"Hoff","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.02.013_bib0036","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 monumental-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.02.013_bib0037","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Usmani","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:38Z","timestamp":1778838578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2152265024000909"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}